91 related articles for article (PubMed ID: 12443881)
1. Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells.
Błasiak J; Gloc E; Młynarski W; Drzewoski J; Skórski T
Leuk Res; 2002 Dec; 26(12):1093-6. PubMed ID: 12443881
[TBL] [Abstract][Full Text] [Related]
2. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine.
Błasiak J; Gloc E; Woźniak K; Młynarski W; Stolarska M; Skórski T; Majsterek I
Chem Biol Interact; 2002 Apr; 140(1):1-18. PubMed ID: 12044557
[TBL] [Abstract][Full Text] [Related]
3. TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine.
Gloc E; Warszawski M; Młynarski W; Stolarska M; Hoser G; Skorski T; Błasiak J
Acta Biochim Pol; 2002; 49(1):121-8. PubMed ID: 12136932
[TBL] [Abstract][Full Text] [Related]
4. DNA damage and repair in BCR/ABL-expressing cells after combined action of idarubicin, STI571 and amifostine.
Blasiak J; Gloc E; Pertyński T; Drzewoski J
Anticancer Drugs; 2002 Nov; 13(10):1055-60. PubMed ID: 12439339
[TBL] [Abstract][Full Text] [Related]
5. TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin.
Majsterek I; Slupianek A; Blasiak J
Anticancer Drugs; 2003 Sep; 14(8):625-31. PubMed ID: 14501384
[TBL] [Abstract][Full Text] [Related]
6. Amifostine can differentially modulate DNA double-strand breaks and apoptosis induced by idarubicin in normal and cancer cells.
Wozniak K; Gloc E; Morawiec Z; Blasiak J
Exp Oncol; 2008 Mar; 30(1):22-8. PubMed ID: 18438337
[TBL] [Abstract][Full Text] [Related]
7. ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance?
Majsterek I; Slupianek A; Hoser G; Skórski T; Blasiak J
Biochimie; 2004 Jan; 86(1):53-65. PubMed ID: 14987801
[TBL] [Abstract][Full Text] [Related]
8. Free radical scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells.
Blasiak J; Gloc E; Drzewoski J; Wozniak K; Zadrozny M; Skórski T; Pertynski T
Mutat Res; 2003 Feb; 535(1):25-34. PubMed ID: 12547280
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the action of amifostine and melatonin on DNA-damaging effects and apoptosis induced by idarubicin in normal and cancer cells.
Majsterek I; Gloc E; Blasiak J; Reiter RJ
J Pineal Res; 2005 May; 38(4):254-63. PubMed ID: 15813902
[TBL] [Abstract][Full Text] [Related]
10. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?
Hoser G; Majsterek I; Romana DL; Slupianek A; Blasiak J; Skorski T
Leuk Res; 2003 Mar; 27(3):267-73. PubMed ID: 12537980
[TBL] [Abstract][Full Text] [Related]
11. Does the bcr/abl-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells?
Majsterek I; Blasiak J; Mlynarski W; Hoser G; Skórski T
Cell Biol Int; 2002; 26(4):363-70. PubMed ID: 11991666
[TBL] [Abstract][Full Text] [Related]
12. Differential antigenotoxic and cytoprotective effect of amifostine in idarubicin-treated mice.
de Campos Nebel M; Larripa I; González-Cid M
Environ Mol Mutagen; 2002; 39(1):3-9. PubMed ID: 11813290
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the in vitro genotoxicity of anticancer drugs idarubicin and mitoxantrone.
Błasiak J; Gloc E; Warszawski M
Acta Biochim Pol; 2002; 49(1):145-55. PubMed ID: 12136935
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of TEL-MN1 Fusion Enhances Resistance of HL-60 Cells to Idarubicin.
Gong S; Guo M; Tang G; Yang J; Qiu H
Chemotherapy; 2018; 63(6):308-314. PubMed ID: 30840968
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
Pytel D; Wysocki T; Majsterek I
Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of amifostine on busulfan induced DNA damage in human hepatoma cells.
Ghassemi-Barghi N; Etebari M; Jafarian-Dehkordi A
Toxicol Mech Methods; 2017 Jan; 27(1):52-57. PubMed ID: 27771991
[TBL] [Abstract][Full Text] [Related]
17. Zinc differentially modulates DNA damage induced by anthracyclines in normal and cancer cells.
Wysokinski D; Blasiak J; Wozniak K
Exp Oncol; 2012 Dec; 34(4):327-31. PubMed ID: 23302990
[TBL] [Abstract][Full Text] [Related]
18. The DNA-damaging potential of tamoxifen in breast cancer and normal cells.
Wozniak K; Kolacinska A; Blasinska-Morawiec M; Morawiec-Bajda A; Morawiec Z; Zadrozny M; Blasiak J
Arch Toxicol; 2007 Jul; 81(7):519-27. PubMed ID: 17593413
[TBL] [Abstract][Full Text] [Related]
19. Dexrazoxane Averts Idarubicin-Evoked Genomic Damage by Regulating Gene Expression Profiling Associated With the DNA Damage-Signaling Pathway in BALB/c Mice.
Attia SM; Alshahrani AY; Al-Hamamah MA; Attia MM; Saquib Q; Ahmad SF; Ansari MA; Nadeem A; Bakheet SA
Toxicol Sci; 2017 Nov; 160(1):161-172. PubMed ID: 28973540
[TBL] [Abstract][Full Text] [Related]
20. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
Czechowska A; Poplawski T; Drzewoski J; Blasiak J
Chem Biol Interact; 2005 Apr; 152(2-3):139-50. PubMed ID: 15840387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
